ZYME - Zymeworks Inc.
About Zymeworks Inc. (https://www.zymeworks.com)
Zymeworks Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to identifying, advancing, and bringing to market biological therapies aimed at combating cancer. Its pipeline features two primary experimental treatments: zanidatamab, a cutting-edge bispecific antibody currently undergoing Phase 1 and Phase 2 studies for various malignancies such as those affecting the biliary tract, gastroesophageal region (adenocarcinomas), breast, and colon; and ZW49, an antibody-drug conjugate targeting two sites on the human epidermal growth factor receptor 2 (HER2), which is in Phase 1 trials for advanced or spreading tumors that express HER2. Zymeworks maintains significant alliances with several pharmaceutical leaders, including Merck Sharp & Dohme Research Ltd., Eli Lilly and Company, Bristol-Myers Squibb company, GlaxoSmithKline Intellectual Property Development Ltd., Daiichi Sankyo Co., Ltd., Janssen Biotech, Inc., BeiGene, Ltd., and Exelixis, Inc. Furthermore, it engages in cooperative research and licensing agreements with LEO Pharma A/S, specifically for the exploration, advancement, and market introduction of bispecific antibodies, and with Iconic Therapeutics, Inc. Established in 2003, Zymeworks Inc. operates from its headquarters located in Vancouver, Canada.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Kenneth H. Galbraith | Chairman of the Board, Chief Executive Officer & President | 1962 | $1,708,375 USD |
| Paul Moore | Chief Scientific Officer | 1968 | $998,368 USD |
| Adam Schayowitz | Executive VP and Head of Research & Development | – | – |
| Alexey Berezhnoy | Director of Immunology | – | – |
| Bijal Desai | Senior Vice President of Finance | – | – |
| Diana Papove | Vice President of Corporate Communications | – | – |
| Kristin Stafford | Executive VP & CFO | 1982 | – |
| Laura O'Connor | Senior VP & Chief Human Resources Officer | – | – |
| Lindsey Foulkes | SVP of Corporate Development & Strategy | – | – |
| Mark Hollywood | Executive VP & Chief Operating Officer | 1969 | – |
| Nina Weisser | Director of Multispecific Antibody Therapeutics | – | – |
| Paul R. Schneider | Executive VP & General Counsel | 1971 | – |
| Ryan Dercho | Senior Director of Corporate Affairs | – | – |
| Scott Platshon | Executive VP & Chief Business Officer | 1991 | – |
| Shrinal Inamdar | VP of Investor Relations | – | – |
| Thomas Spreter Von Kreudenstein | Director of Protein Engineering | – | – |